BioMedTech Press Release

Carmat: CE marking for its total artificial heart

"The CE Marking is great news for patients and a major milestone for CARMAT. As early as January, we will accelerate the ramp-up of our manufacturing activities and intensify discussions with our core target customers in order to achieve a smooth commercial launch during the second quarter of 2021, and thus offer a solution to many patients waiting for a heart transplant." Stéphane Piat, Carmat CEO

  • CE marking allows the company to market its total artificial heart in the EU as a bridge to transplant

  • Virtual press conference scheduled on January 6, 2021